Share on StockTwits

bluebird bio (NASDAQ:BLUE) CEO Nick Leschly sold 10,300 shares of the stock on the open market in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $38.45, for a total value of $396,035.00. Following the sale, the chief executive officer now directly owns 315,001 shares in the company, valued at approximately $12,111,788. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Shares of bluebird bio (NASDAQ:BLUE) traded down 1.32% on Wednesday, hitting $38.03. 222,013 shares of the company’s stock traded hands. bluebird bio has a 1-year low of $17.03 and a 1-year high of $41.75. The stock’s 50-day moving average is $34.90 and its 200-day moving average is $28.14. The company’s market cap is $1.087 billion.

bluebird bio (NASDAQ:BLUE) last released its earnings data on Tuesday, August 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.39. The company had revenue of $6.30 million for the quarter, compared to the consensus estimate of $6.15 million. Analysts expect that bluebird bio will post $-1.69 EPS for the current fiscal year.

A number of analysts have recently weighed in on BLUE shares. Analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of bluebird bio in a research note on Wednesday, June 18th. They now have a $53.00 price target on the stock, up previously from $44.00. Separately, analysts at Wedbush raised their price target on shares of bluebird bio to $51.00 in a research note on Monday, June 16th. Finally, analysts at Piper Jaffray initiated coverage on shares of bluebird bio in a research note on Friday, June 13th. They set an “overweight” rating on the stock.

bluebird bio, Inc is a clinical-stage biotechnology company, the Company is focused on transforming the lives of patients with severe genetic and orphan diseases using gene therapy.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.